Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACKR3 | P25106 | 2/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 12/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19926244 | 0.89 | ACKR3 (0.46) | ACKR3OPRM1OPRD1CHRNB2CHRNB4 | |
| SCHEMBL19926249 | 0.88 | ACKR3 (0.56) | ACKR3OPRM1OPRD1CHRNB2CHRNB4 | |
| SCHEMBL19926090 | 0.88 | ACKR3 (0.45) | ACKR3OPRM1OPRD1CHRNB2CHRNB4 | |
| SCHEMBL19925898 | 0.88 | ACKR3 (0.47) | ACKR3OPRM1OPRD1CHRNB2CHRNB4 | |
| SCHEMBL19926282 | 0.88 | OPRM1 (0.52) | ACKR3OPRM1OPRD1CHRNB2CHRNB4 | |
| SCHEMBL19926157 | 0.87 | ACKR3 (0.54) | ACKR3OPRM1OPRD1CHRNB2CHRNB4 | |
| SCHEMBL19926256 | 0.78 | ACKR3 (0.48) | ACKR3OPRM1OPRD1CHRNB2CHRNB4 | |
| SCHEMBL19926199 | 0.78 | ACKR3 (0.48) | ACKR3OPRM1OPRD1CHRNB2CHRNB4 | |
| SCHEMBL19925902 | 0.78 | ACKR3 (0.45) | ACKR3OPRM1OPRD1CHRNB2CHRNB4 | |
| SCHEMBL30142490 | 0.78 | ACKR3 (0.45) | ACKR3OPRM1OPRD1CHRNB2CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220315567-A1 | Substituted Ureas and Methods of Making and Using Same | MEBIAS DISCOVERY, INC. | 2022-10-06 | — | — | US | claimed |
| US-20200308155-A1 | Substituted Ureas and Methods of Making and Using Same | MEBIAS DISCOVERY, INC. | 2020-10-01 | — | — | US | claimed |
| EP-3506983-A1 | SUBSTITUTED UREAS AND METHODS OF MAKING AND USING SAME | Mebias Discovery LLC (US) | 2019-07-10 | — | — | EP | claimed |
| US-20190194178-A1 | SUBSTITUTED UREAS AND METHODS OF MAKING AND USING SAME | MEBIAS DISCOVERY LLC | 2019-06-27 | — | — | US | claimed |
| WO-2018045229-A1 | SUBSTITUTED UREAS AND METHODS OF MAKING AND USING SAME | MEBIAS DISCOVERY LLC (US) | 2018-03-08 | — | — | WO | claimed |
| US-20220315567-A1 | Substituted Ureas and Methods of Making and Using Same | MEBIAS DISCOVERY, INC. | 2022-10-06 | — | — | US | disclosed |
| US-11198685-B2 | Substituted ureas and methods of making and using same | MEBIAS DISCOVERY, INC. (US) | 2021-12-14 | — | — | US | disclosed |
| US-20200308155-A1 | Substituted Ureas and Methods of Making and Using Same | MEBIAS DISCOVERY, INC. | 2020-10-01 | — | — | US | disclosed |
| US-10683283-B2 | Substituted ureas and methods of making and using same | MEBIAS DISCOVERY, INC. (US) | 2020-06-16 | — | — | US | disclosed |
| EP-3506983-A1 | SUBSTITUTED UREAS AND METHODS OF MAKING AND USING SAME | Mebias Discovery LLC (US) | 2019-07-10 | — | — | EP | disclosed |
| US-20190194178-A1 | SUBSTITUTED UREAS AND METHODS OF MAKING AND USING SAME | MEBIAS DISCOVERY LLC | 2019-06-27 | — | — | US | disclosed |
| WO-2018045229-A1 | SUBSTITUTED UREAS AND METHODS OF MAKING AND USING SAME | MEBIAS DISCOVERY LLC (US) | 2018-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10683283-B2 | Substituted ureas and methods of making and using same | UMPS, METTL3, UTS2R | ACKR3 2484/4885OPRM1 178/4885OPRD1 868/4885 |
| US-20220315567-A1 | Substituted Ureas and Methods of Making and Using Same | UMPS, METTL3, UTS2R | ACKR3 2484/4885OPRM1 178/4885OPRD1 868/4885 |
| US-20190194178-A1 | SUBSTITUTED UREAS AND METHODS OF MAKING AND USING SAME | UMPS, METTL3, UTS2R | ACKR3 2484/4885OPRM1 178/4885OPRD1 868/4885 |
| US-11198685-B2 | Substituted ureas and methods of making and using same | UMPS, METTL3, UTS2R | ACKR3 2484/4885OPRM1 178/4885OPRD1 868/4885 |
| US-20200308155-A1 | Substituted Ureas and Methods of Making and Using Same | UMPS, METTL3, UTS2R | ACKR3 2484/4885OPRM1 178/4885OPRD1 868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.